Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Australasian Leukaemia and Lymphoma Group (ALLG)
Scientific Title
A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity in elderly patients with chronic myelogenous leukaemia.